Research Article
Altered Pulmonary Lymphatic Development in Infants with Chronic Lung Disease
Table 1
Clinical variables of controls and infants with CLD.
| | Controls | CLD* | | Qualitative | Quantitative |
| Number | 9 | 4 | 9 | Gestational age, weeks | | | | Postmenstrual age (PMA) | NA | NA | | Birth weight, kg | | | | Ventilator days | | | | Days lived | | | | % antenatal steroids | 11 | 0 | 42 | % surfactant | 33 | 50 | 71 | % RDS (moderate to severe) | 0 | 0 | 71 | % postnatal steroids | 11 | 0 | 71 | Cause of death | | | | Respiratory failure | 0 | 0 | 3 | Extreme immaturity (died in DR) | 1 | 0 | 0 | Intracranial hemorrhage, grade IV | 1 | 0 | 0 | NEC | 0 | 0 | 2 | DIC/other hemorrhage | 2 | 1 | 1 | HIE/encephalomalacia | 3 | 2 | 0 | Sepsis/pneumonia | 1 | 1 | 1 | Other | 1 | 0 | 2 |
|
|
Average ± standard deviation.
*Complete clinical data available for 7 CLD infants.
|